Baseline Anthropometric & Lipid Assessment
PCOS raises lifelong cardiometabolic risk beyond reproductive symptoms alone.
- ~10%: PCOS prevalence (of reproductive-age women)
- ~43%: Metabolic synd. in PCOS (vs ~24% in controls)
- 88 cm: Central obesity threshold (waist, per ATP III women)
- 50–70%: Insulin resistance rate (across PCOS phenotypes)
Why anthropometrics anchor the model
BMI and waist circumference proxy visceral fat burden cheaply.
Lipid panel inputs
Triglycerides and HDL cholesterol flag early dyslipidemia patterns.
Why PCOS changes the baseline
Androgen excess independently worsens fat distribution and lipids.
Waist circumference predicts risk better than BMI alone in PCOS.
Hyperinsulinemia & Insulin Resistance
Compensatory hyperinsulinemia is the metabolic engine behind PCOS risk.
- 50–70%: Insulin resistance in PCOS (lean and obese phenotypes)
- >2.5: HOMA-IR elevated cutoff (common research threshold)
- ↑↑: Hepatic lipogenesis boost (driven by hyperinsulinemia)
- ~10–15: Beta-cell compensation years (before overt dysglycemia)
Insulin and the ovary-liver axis
Excess insulin amplifies ovarian androgen output and hepatic fat synthesis.
Pancreatic beta-cell strain
Beta cells overproduce insulin for years before failure appears.
Downstream cascade
Insulin resistance seeds both dyslipidemia and hepatic fat.
Insulin resistance is the common root of three later risks.
Atherogenic Dyslipidemia Risk
PCOS produces a distinct high-triglyceride, low-HDL lipid signature.
- ~30–40%: Elevated triglycerides (of PCOS patients)
- ~30%: Low HDL prevalence (below protective threshold)
- Small, dense: LDL particle shift (more atherogenic subtype)
- Early: Dyslipidemia onset (often before age 30)
The PCOS lipid signature
High triglycerides pair with stubbornly low HDL cholesterol.
Vascular consequence
Small dense LDL particles infiltrate arterial walls more readily.
Waist as the driver
Visceral fat directly fuels triglyceride overproduction in the liver.
Waist circumference tracks dyslipidemia tighter than BMI does.
Non-Alcoholic Fatty Liver Disease Risk
Hepatic fat quietly accumulates as insulin resistance persists untreated.
- ~35–70%: NAFLD prevalence in PCOS (vs ~20–30% general pop.)
- Yes: Independent of BMI (lean PCOS still at risk)
- ~20%: Progression to NASH (of NAFLD cases)
- Early: Reversibility window (with weight and insulin control)
How fat accumulates in the liver
Excess insulin pushes the liver to store fat instead of exporting it.
Why PCOS liver risk is distinct
Androgen excess compounds insulin-driven hepatic lipid accumulation.
Screening implication
Liver enzymes and imaging are underused in PCOS follow-up.
NAFLD risk rises steeply once BMI crosses the obese range.
Cumulative Type 2 Diabetes & Cardiometabolic Risk
All prior risk streams converge into one composite score.
- 4–8×: T2D risk in PCOS (higher than age-matched peers)
- ~30–40%: Prediabetes prevalence (by reproductive age)
- ~2×: Cardiovascular event risk (elevated lifetime risk)
- 0–100: Composite score range (this simulator's scale)
Combining the risk streams
Insulin resistance, dyslipidemia, and NAFLD sum into one gauge.
Why early calculation matters
Earlier detection allows lifestyle intervention before disease onset.
Using the composite score
Higher scores flag candidates for closer metabolic monitoring.
The composite score is illustrative, not a diagnostic instrument.